ProMIS Neurosciences, Inc. (PMN)
| Previous Close | 1.0200 |
| Open | 1.0500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.0200 - 1.0876 |
| 52 Week Range | 0.9200 - 3.1000 |
| Volume | |
| Avg. Volume | 68,793 |
| Market Cap | 31.679M |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.75 |
GlobeNewswireProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer’s disease patients planned for year-end 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases
- GlobeNewswire
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that preclinical data supporting the potential role of its lead product candidate, PMN310, as a trea
